Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions.

Kim K, Hessl D, Randol JL, Espinal GM, Schneider A, Protic D, Aydin EY, Hagerman RJ, Hagerman PJ.

PLoS One. 2019 Dec 31;14(12):e0226811. doi: 10.1371/journal.pone.0226811. eCollection 2019.

2.

Interaction between ventricular expansion and structural changes in the corpus callosum and putamen in males with FMR1 normal and premutation alleles.

Wang JY, Hessl D, Tassone F, Kim K, Hagerman RJ, Rivera SM.

Neurobiol Aging. 2019 Sep 24. pii: S0197-4580(19)30330-6. doi: 10.1016/j.neurobiolaging.2019.09.009. [Epub ahead of print]

PMID:
31733943
3.

Cognitive training for children and adolescents with fragile X syndrome: a randomized controlled trial of Cogmed.

Hessl D, Schweitzer JB, Nguyen DV, McLennan YA, Johnston C, Shickman R, Chen Y.

J Neurodev Disord. 2019 Apr 15;11(1):4. doi: 10.1186/s11689-019-9264-2.

4.

Voice of People with Fragile X Syndrome and Their Families: Reports from a Survey on Treatment Priorities.

Weber JD, Smith E, Berry-Kravis E, Cadavid D, Hessl D, Erickson C.

Brain Sci. 2019 Jan 23;9(2). pii: E18. doi: 10.3390/brainsci9020018.

5.

Executive Function in Fragile X Syndrome: A Systematic Review.

Schmitt LM, Shaffer RC, Hessl D, Erickson C.

Brain Sci. 2019 Jan 16;9(1). pii: E15. doi: 10.3390/brainsci9010015. Review.

6.

Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.

Hessl D, Harvey D, Sansone S, Crestodina C, Chin J, Joshi R, Hagerman RJ, Berry-Kravis E.

PLoS One. 2019 Jan 17;14(1):e0209984. doi: 10.1371/journal.pone.0209984. eCollection 2019.

7.

Best Practices in Fragile X Syndrome Treatment Development.

Erickson CA, Kaufmann WE, Budimirovic DB, Lachiewicz A, Haas-Givler B, Miller RM, Weber JD, Abbeduto L, Hessl D, Hagerman RJ, Berry-Kravis E.

Brain Sci. 2018 Dec 15;8(12). pii: E224. doi: 10.3390/brainsci8120224.

8.

Extending the Parent-Delivered Early Start Denver Model to Young Children with Fragile X Syndrome.

Vismara LA, McCormick CEB, Shields R, Hessl D.

J Autism Dev Disord. 2019 Mar;49(3):1250-1266. doi: 10.1007/s10803-018-3833-1.

PMID:
30499037
9.

Standardized Assessment Accommodations for Individuals with Intellectual Disability.

Thompson T, Coleman JM, Riley K, Snider LA, Howard LJ, Sansone SM, Hessl D.

Contemp Sch Psychol. 2018 Dec;22(4):443-457. doi: 10.1007/s40688-018-0171-4. Epub 2018 Jan 23. No abstract available.

10.

Assessment of Molecular Measures in Non-FXTAS Male Premutation Carriers.

Al Olaby RR, Tang HT, Durbin-Johnson B, Schneider A, Hessl D, Rivera SM, Tassone F.

Front Genet. 2018 Aug 22;9:302. doi: 10.3389/fgene.2018.00302. eCollection 2018.

11.

Presence of Middle Cerebellar Peduncle Sign in FMR1 Premutation Carriers Without Tremor and Ataxia.

Famula JL, McKenzie F, McLennan YA, Grigsby J, Tassone F, Hessl D, Rivera SM, Martinez-Cerdeno V, Hagerman RJ.

Front Neurol. 2018 Aug 22;9:695. doi: 10.3389/fneur.2018.00695. eCollection 2018.

12.

Middle Cerebellar Peduncle Width-A Novel MRI Biomarker for FXTAS?

Shelton AL, Wang JY, Fourie E, Tassone F, Chen A, Frizzi L, Hagerman RJ, Ferrer E, Hessl D, Rivera SM.

Front Neurosci. 2018 Jun 25;12:379. doi: 10.3389/fnins.2018.00379. eCollection 2018.

13.

Computerized Cognitive Training in Children With Autism and Intellectual Disabilities: Feasibility and Satisfaction Study.

Benyakorn S, Calub CA, Riley SJ, Schneider A, Iosif AM, Solomon M, Hessl D, Schweitzer JB.

JMIR Ment Health. 2018 May 25;5(2):e40. doi: 10.2196/mental.9564.

14.

Age- and CGG repeat-related slowing of manual movement in fragile X carriers: A prodrome of fragile X-associated tremor ataxia syndrome?

Shickman R, Famula J, Tassone F, Leehey M, Ferrer E, Rivera SM, Hessl D.

Mov Disord. 2018 Apr;33(4):628-636. doi: 10.1002/mds.27314. Epub 2018 Feb 1.

15.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S.

Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Review.

16.

Clinical and molecular correlates in fragile X premutation females.

Jiraanont P, Sweha SR, AlOlaby RR, Silva M, Tang HT, Durbin-Johnson B, Schneider A, Espinal GM, Hagerman PJ, Rivera SM, Hessl D, Hagerman RJ, Chutabhakdikul N, Tassone F.

eNeurologicalSci. 2017 Jun;7:49-56. doi: 10.1016/j.ensci.2017.04.003. Epub 2017 Apr 11.

17.

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Youssef EA, Berry-Kravis E, Czech C, Hagerman RJ, Hessl D, Wong CY, Rabbia M, Deptula D, John A, Kinch R, Drewitt P, Lindemann L, Marcinowski M, Langland R, Horn C, Fontoura P, Santarelli L, Quiroz JA; FragXis Study Group.

Neuropsychopharmacology. 2018 Feb;43(3):503-512. doi: 10.1038/npp.2017.177. Epub 2017 Aug 17.

18.

A randomized double-blind, placebo-controlled trial of ganaxolone in children and adolescents with fragile X syndrome.

Ligsay A, Van Dijck A, Nguyen DV, Lozano R, Chen Y, Bickel ES, Hessl D, Schneider A, Angkustsiri K, Tassone F, Ceulemans B, Kooy RF, Hagerman RJ.

J Neurodev Disord. 2017 Aug 2;9(1):26. doi: 10.1186/s11689-017-9207-8.

19.

Updated report on tools to measure outcomes of clinical trials in fragile X syndrome.

Budimirovic DB, Berry-Kravis E, Erickson CA, Hall SS, Hessl D, Reiss AL, King MK, Abbeduto L, Kaufmann WE.

J Neurodev Disord. 2017 Jun 12;9:14. doi: 10.1186/s11689-017-9193-x. eCollection 2017. Review.

20.

Fragile X targeted pharmacotherapy: lessons learned and future directions.

Erickson CA, Davenport MH, Schaefer TL, Wink LK, Pedapati EV, Sweeney JA, Fitzpatrick SE, Brown WT, Budimirovic D, Hagerman RJ, Hessl D, Kaufmann WE, Berry-Kravis E.

J Neurodev Disord. 2017 Jun 12;9:7. doi: 10.1186/s11689-017-9186-9. eCollection 2017. Review.

21.

Abnormal trajectories in cerebellum and brainstem volumes in carriers of the fragile X premutation.

Wang JY, Hessl D, Hagerman RJ, Simon TJ, Tassone F, Ferrer E, Rivera SM.

Neurobiol Aging. 2017 Jul;55:11-19. doi: 10.1016/j.neurobiolaging.2017.03.018. Epub 2017 Mar 18.

22.

Autism Spectrum Disorder in Males with Sex Chromosome Aneuploidy: XXY/Klinefelter Syndrome, XYY, and XXYY.

Tartaglia NR, Wilson R, Miller JS, Rafalko J, Cordeiro L, Davis S, Hessl D, Ross J.

J Dev Behav Pediatr. 2017 Apr;38(3):197-207. doi: 10.1097/DBP.0000000000000429.

23.

Psychiatric disorders among women with the fragile X premutation without children affected by fragile X syndrome.

Gossett A, Sansone S, Schneider A, Johnston C, Hagerman R, Tassone F, Rivera SM, Seritan AL, Hessl D.

Am J Med Genet B Neuropsychiatr Genet. 2016 Dec;171(8):1139-1147. doi: 10.1002/ajmg.b.32496. Epub 2016 Sep 12.

24.

The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions.

Hessl D, Sansone SM, Berry-Kravis E, Riley K, Widaman KF, Abbeduto L, Schneider A, Coleman J, Oaklander D, Rhodes KC, Gershon RC.

J Neurodev Disord. 2016 Sep 6;8(1):35. doi: 10.1186/s11689-016-9167-4. eCollection 2016.

25.

A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome.

Greiss Hess L, Fitzpatrick SE, Nguyen DV, Chen Y, Gaul KN, Schneider A, Lemons Chitwood K, Eldeeb MA, Polussa J, Hessl D, Rivera S, Hagerman RJ.

J Dev Behav Pediatr. 2016 Oct;37(8):619-28. doi: 10.1097/DBP.0000000000000334.

26.

Broad autism spectrum and obsessive-compulsive symptoms in adults with the fragile X premutation.

Schneider A, Johnston C, Tassone F, Sansone S, Hagerman RJ, Ferrer E, Rivera SM, Hessl D.

Clin Neuropsychol. 2016 Aug;30(6):929-43. doi: 10.1080/13854046.2016.1189536. Epub 2016 Jun 29.

27.

Fragile X-associated tremor/ataxia syndrome: another phenotype of the fragile X gene.

Hessl D, Grigsby J.

Clin Neuropsychol. 2016 Aug;30(6):810-4. doi: 10.1080/13854046.2016.1186661. Epub 2016 Jun 29.

28.

Aging in Fragile X Premutation Carriers.

Lozano R, Saito N, Reed D, Eldeeb M, Schneider A, Hessl D, Tassone F, Beckett L, Hagerman R.

Cerebellum. 2016 Oct;15(5):587-94. doi: 10.1007/s12311-016-0805-x.

PMID:
27334385
29.

Robust Machine Learning-Based Correction on Automatic Segmentation of the Cerebellum and Brainstem.

Wang JY, Ngo MM, Hessl D, Hagerman RJ, Rivera SM.

PLoS One. 2016 May 23;11(5):e0156123. doi: 10.1371/journal.pone.0156123. eCollection 2016.

30.

The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery.

Brick DJ, Nethercott HE, Montesano S, Banuelos MG, Stover AE, Schutte SS, O'Dowd DK, Hagerman RJ, Ono M, Hessl DR, Tassone F, Schwartz PH.

Stem Cells Transl Med. 2015 Nov;4(11):1369. doi: 10.5966/sctm.2014-0073erratum. No abstract available.

31.

Anxiety disorders in fragile X premutation carriers: Preliminary characterization of probands and non-probands.

Cordeiro L, Abucayan F, Hagerman R, Tassone F, Hessl D.

Intractable Rare Dis Res. 2015 Aug;4(3):123-30. doi: 10.5582/irdr.2015.01029.

32.

The Autism Spectrum Disorders Stem Cell Resource at Children's Hospital of Orange County: Implications for Disease Modeling and Drug Discovery.

Brick DJ, Nethercott HE, Montesano S, Banuelos MG, Stover AE, Schutte SS, O'Dowd DK, Hagerman RJ, Ono M, Hessl DR, Tassone F, Schwartz PH.

Stem Cells Transl Med. 2014 Nov;3(11):1275-86. doi: 10.5966/sctm.2014-0073. Epub 2014 Oct 1. Erratum in: Stem Cells Transl Med. 2015 Nov;4(11):1369.

33.

A feasibility trial of Cogmed working memory training in fragile X syndrome.

Au J, Berkowitz-Sutherland L, Schneider A, Schweitzer JB, Hessl D, Hagerman R.

J Pediatr Genet. 2014 Sep;3(3):147-56. doi: 10.3233/PGE-14098.

34.

Association between macroorchidism and intelligence in FMR1 premutation carriers.

Lozano R, Summers S, Lozano C, Mu Y, Hessl D, Nguyen D, Tassone F, Hagerman R.

Am J Med Genet A. 2014 Sep;164A(9):2206-11. doi: 10.1002/ajmg.a.36624. Epub 2014 Jun 5.

35.

Emotion potentiated startle in fragile X syndrome.

Ballinger EC, Cordeiro L, Chavez AD, Hagerman RJ, Hessl D.

J Autism Dev Disord. 2014 Oct;44(10):2536-46. doi: 10.1007/s10803-014-2125-7.

36.

Electrodermal and behavioral responses of children with autism spectrum disorders to sensory and repetitive stimuli.

McCormick C, Hessl D, Macari SL, Ozonoff S, Green C, Rogers SJ.

Autism Res. 2014 Aug;7(4):468-80. doi: 10.1002/aur.1382. Epub 2014 Apr 30.

37.

Feasibility, reproducibility, and clinical validity of the pediatric anxiety rating scale-revised for fragile X syndrome.

Russo-Ponsaran NM, Yesensky J, Hessl D, Berry-Kravis E.

Am J Intellect Dev Disabil. 2014 Jan;119(1):1-16. doi: 10.1352/1944-7558-119.1.1.

38.

Psychological status in female carriers of premutation FMR1 allele showing a complex relationship with the size of CGG expansion.

Loesch DZ, Bui MQ, Hammersley E, Schneider A, Storey E, Stimpson P, Burgess T, Francis D, Slater H, Tassone F, Hagerman RJ, Hessl D.

Clin Genet. 2015 Feb;87(2):173-8. doi: 10.1111/cge.12347. Epub 2014 Feb 17.

39.

Improving IQ measurement in intellectual disabilities using true deviation from population norms.

Sansone SM, Schneider A, Bickel E, Berry-Kravis E, Prescott C, Hessl D.

J Neurodev Disord. 2014;6(1):16. doi: 10.1186/1866-1955-6-16. Epub 2014 Jul 8.

40.

Anxiety, attention problems, hyperactivity, and the Aberrant Behavior Checklist in fragile X syndrome.

Wheeler A, Raspa M, Bann C, Bishop E, Hessl D, Sacco P, Bailey DB Jr.

Am J Med Genet A. 2014 Jan;164A(1):141-55. doi: 10.1002/ajmg.a.36232. Epub 2013 Nov 25.

PMID:
24352914
41.

Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome.

Cohen S, Masyn K, Mastergeorge A, Hessl D.

J Clin Child Adolesc Psychol. 2015;44(2):250-63. doi: 10.1080/15374416.2013.843462. Epub 2013 Oct 24.

42.

Outcome measures for clinical trials in fragile X syndrome.

Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK; Outcome Measures Working Groups.

J Dev Behav Pediatr. 2013 Sep;34(7):508-22. doi: 10.1097/DBP.0b013e31829d1f20.

43.

Electrocortical changes associated with minocycline treatment in fragile X syndrome.

Schneider A, Leigh MJ, Adams P, Nanakul R, Chechi T, Olichney J, Hagerman R, Hessl D.

J Psychopharmacol. 2013 Oct;27(10):956-63. doi: 10.1177/0269881113494105. Epub 2013 Aug 27.

44.

Psychiatric features in high-functioning adult brothers with fragile x spectrum disorders.

Schneider A, Seritan A, Tassone F, Rivera SM, Hagerman R, Hessl D.

Prim Care Companion CNS Disord. 2013;15(2). pii: PCC.12l01492. doi: 10.4088/PCC.12l01492. No abstract available.

45.

A family with two female siblings with compound heterozygous FMR1 premutation alleles.

Basuta K, Lozano R, Schneider A, Yrigollen CM, Hessl D, Hagerman RJ, Tassone F.

Clin Genet. 2014 May;85(5):458-63. doi: 10.1111/cge.12218. Epub 2013 Jul 28.

46.

Fragile X-associated tremor/ataxia syndrome: influence of the FMR1 gene on motor fiber tracts in males with normal and premutation alleles.

Wang JY, Hessl D, Schneider A, Tassone F, Hagerman RJ, Rivera SM.

JAMA Neurol. 2013 Aug;70(8):1022-9. doi: 10.1001/jamaneurol.2013.2934.

47.

A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome.

Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, Polussa J, Doucet P, Tassone F, Rivera SM, Hessl D, Hagerman RJ.

J Dev Behav Pediatr. 2013 Apr;34(3):147-55. doi: 10.1097/DBP.0b013e318287cd17.

48.

FRAGILE X SYNDROME: PSYCHIATRIC MANIFESTATIONS, ASSESSMENT AND EMERGING THERAPIES.

Wadell PM, Hagerman RJ, Hessl DR.

Curr Psychiatry Rev. 2013 Feb 1;9(1):53-58.

49.

Fear-specific amygdala function in children and adolescents on the fragile x spectrum: a dosage response of the FMR1 gene.

Kim SY, Burris J, Bassal F, Koldewyn K, Chattarji S, Tassone F, Hessl D, Rivera SM.

Cereb Cortex. 2014 Mar;24(3):600-13. doi: 10.1093/cercor/bhs341. Epub 2012 Nov 11.

50.

Male carriers of the FMR1 premutation show altered hippocampal-prefrontal function during memory encoding.

Wang JM, Koldewyn K, Hashimoto R, Schneider A, Le L, Tassone F, Cheung K, Hagerman P, Hessl D, Rivera SM.

Front Hum Neurosci. 2012 Oct 30;6:297. doi: 10.3389/fnhum.2012.00297. eCollection 2012.

Supplemental Content

Support Center